Get the Stockscreener App
8.65
2.26%
-0.20
After Hours:
8.70
0.05
+0.58%
Celcuity Inc stock is traded at $8.65, with a volume of 502.14K.
It is down -2.26% in the last 24 hours and down -12.98% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$8.85
Open:
$8.58
24h Volume:
502.14K
Relative Volume:
1.88
Market Cap:
$327.31M
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-3.2276
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
-15.53%
1M Performance:
-12.98%
6M Performance:
-42.49%
1Y Performance:
-56.53%
1-Day Range:
$7.70
$8.89
1-Week Range:
$7.70
$10.91
52-Week Range:
$7.70
$20.15
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
8.65 | 327.31M | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Celcuity Stock Hits 52-Week Low at $8.46 Amid Market Challenges - Investing.com India
Research Analysts Offer Predictions for Celcuity Q1 Earnings - Defense World
Celcuity Announces Closing of Common Stock Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock - ACCESS Newswire
Celcuity (NASDAQ:CELC) Receives Buy Rating from Needham & Company LLC - Defense World
Brokerages Set Celcuity Inc. (NASDAQ:CELC) PT at $30.17 - Defense World
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - ACCESS Newswire
Celcuity Inc. Earnings Call Highlights Progress and Challenges - TipRanks
Celcuity Inc (NASDAQ:CELC) Misses Earning Expectations - FXDailyReport.Com
Stifel maintains Celcuity stock Buy rating, $42 target By Investing.com - Investing.com South Africa
Stifel maintains Celcuity stock Buy rating, $42 target - Investing.com India
Celcuity Inc. (NASDAQ:CELC) Q4 2024 Earnings Call Transcript - Insider Monkey
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences - GlobeNewswire
Celcuity Inc. Reports 2024 Financial Results and Clinical Updates - TipRanks
Earnings call transcript: Celcuity Q4 2024 reveals wider losses By Investing.com - Investing.com Canada
Celcuity Inc. SEC 10-K Report - TradingView
Celcuity Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CELCUITY Earnings Results: $CELC Reports Quarterly Earnings - Nasdaq
Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Earnings Scheduled For March 31, 2025 - Benzinga
(CELC) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Has $3.11 Million Stock Position in Celcuity Inc. (NASDAQ:CELC) - Defense World
Bank of New York Mellon Corp Buys 10,828 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call - GlobeNewswire
Celcuity (CELC) Projected to Post Quarterly Earnings on Wednesday - Defense World
Celcuity at Leerink Global Healthcare Conference: Promising Cancer Drug Insights By Investing.com - Investing.com South Africa
Celcuity at Leerink Global Healthcare Conference: Promising Cancer Drug Insights - Investing.com Canada
BlackRock, Inc. Expands Holdings with Celcuity Inc. Acquisition - GuruFocus
Rhumbline Advisers Boosts Position in Celcuity Inc. (NASDAQ:CELC) - Defense World
(CELC) Technical Data - Stock Traders Daily
Brokerages Set Celcuity Inc. (NASDAQ:CELC) Target Price at $30.17 - Defense World
Celcuity, Inc. to Host Earnings Call - ACCESS Newswire
New York State Common Retirement Fund Purchases 3,682 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 - The Malaysian Reserve
(CELC) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Celcuity stock touches 52-week low at $10.35 amid market challenges - Investing.com India
Celcuity stock touches 52-week low at $10.35 amid market challenges By Investing.com - Investing.com South Africa
Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences - The Manila Times
Celcuity Inc. (NASDAQ:CELC) Short Interest Up 6.4% in January - MarketBeat
Celcuity Set to Join Russell 2000 and 3000 Indexes - ACCESS Newswire
Celcuity’s High-Stakes Oncology Bet Is Underappreciated (NASDAQ:CELC) - Seeking Alpha
Q1 Earnings Forecast for Celcuity Issued By Leerink Partnrs - MarketBeat
Bleakley Financial Group LLC Acquires Shares of 11,159 Celcuity Inc. (NASDAQ:CELC) - Defense World
Q2 Earnings Estimate for Celcuity Issued By Leerink Partnrs - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Given Average Rating of "Buy" by Analysts - MarketBeat
Needham & Company LLC Issues Positive Forecast for Celcuity (NASDAQ:CELC) Stock Price - MarketBeat
Q1 Earnings Estimate for Celcuity Issued By Leerink Partnrs - Defense World
Celcuity Inc. (NASDAQ:CELC) Receives $30.17 Consensus Price Target from Brokerages - Defense World
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):